87866-12-4

Basic information

• Product Name: 2-chloro-1-(6-nitroindolin-1-yl)ethan-1-one
• CAS NO: 87866-12-4
• Molecular Weight: 240.646
• Mol File: 87866-12-4.mol

Chemical Properties

• CAS DataBase Reference: 2-chloro-1-(6-nitroindolin-1-yl)ethan-1-one(CAS DataBase Reference)
• NIST Chemistry Reference: 2-chloro-1-(6-nitroindolin-1-yl)ethan-1-one(87866-12-4)
• EPA Substance Registry System: 2-chloro-1-(6-nitroindolin-1-yl)ethan-1-one(87866-12-4)

Safety Data

• Hazardous Substances Data: 87866-12-4(Hazardous Substances Data)

Upstream product

• 19727-83-4 6-nitroindoline 
• 79-04-9 chloroacetyl chloride 
• 4769-96-4 6-nitroindole 

Relevant articles and documents

5HT1F RECEPTOR AGONISTS AND MITOCHONDRIAL BIOGENESIS

Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, promote mitochondrial biogenesis and are useful for the treatment of, for example, acute kidney injury and chronic kidney disease.

Discovery of cis - N -(1-(4-(methylamino)cyclohexyl)indolin-6-yl)thiophene- 2-carboximidamide: A 1,6-disubstituted indoline derivative as a highly selective inhibitor of human neuronal nitric oxide synthase (nNOS) without any cardiovascular liabilities

A series of 1,6-disubstituted indoline derivatives were synthesized and evaluated as inhibitors of human nitric oxide synthase (NOS) designed to mitigate the cardiovascular liabilities associated with previously reported tetrahydroquinoline-based selectiv

Substituted alkylamine derivatives and methods of use

Selected amines are effective for prophylaxis and treatment of diseases, such as angiogenesis mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

Indoline and piperazine containing derivatives as a novel class of mixed D2/D4 receptor antagonists. Part 1: Identification and structure-activity relationships

Optimization of the lead compound 2-[-4-(4-chloro-benzyl)-piperazin-1-yl]-1-(2,3-dihydro-indol-1-yl)-ethanone 1 by systematic structure-activity relation (SAR) studies lead to two potent compounds 2-[-4-(4-chloro-benzyl)-piperazin-1-yl]-1-(2-methy-2,3-dihydro-indol-1-yl)- ethanone 2n and 2-[-4-(4-chloro-benzyl)-piperazin-1-yl]-1-(2-methy-2,3-dihydro-indol-1-yl)- ethanone 7b. Their related synthesis was also reported.